193 related articles for article (PubMed ID: 8931935)
21. Discovery of novel tubulin inhibitors via structure-based hierarchical virtual screening.
Cao R; Liu M; Yin M; Liu Q; Wang Y; Huang N
J Chem Inf Model; 2012 Oct; 52(10):2730-40. PubMed ID: 22992059
[TBL] [Abstract][Full Text] [Related]
22. Synthesis, biological evaluation and molecular modeling of 1,2,3-triazole analogs of combretastatin A-1.
Akselsen OW; Odlo K; Cheng JJ; Maccari G; Botta M; Hansen TV
Bioorg Med Chem; 2012 Jan; 20(1):234-42. PubMed ID: 22137934
[TBL] [Abstract][Full Text] [Related]
23. Biological evaluation and molecular modelling study of podophyllotoxin derivatives as potent inhibitors of tubulin polymerization.
Ma Y; Fang S; Li H; Han C; Lu Y; Zhao Y; Liu Y; Zhao C
Chem Biol Drug Des; 2013 Jul; 82(1):12-21. PubMed ID: 23786349
[TBL] [Abstract][Full Text] [Related]
24. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin.
Lin CM; Ho HH; Pettit GR; Hamel E
Biochemistry; 1989 Aug; 28(17):6984-91. PubMed ID: 2819042
[TBL] [Abstract][Full Text] [Related]
25. Antimitotic and antitubulin activity of the tumor inhibitor steganacin.
Wang RW; Rebhum LI; Kupchan SM
Cancer Res; 1977 Sep; 37(9):3071-9. PubMed ID: 560248
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, Biological Evaluation, and Molecular Docking of Combretastatin and Colchicine Derivatives and their hCE1-Activated Prodrugs as Antiviral Agents.
Richter M; Boldescu V; Graf D; Streicher F; Dimoglo A; Bartenschlager R; Klein CD
ChemMedChem; 2019 Feb; 14(4):469-483. PubMed ID: 30605241
[TBL] [Abstract][Full Text] [Related]
27. Structure of 4'-demethylepipodophyllotoxin in complex with tubulin provides a rationale for drug design.
Niu L; Wang Y; Wang C; Wang Y; Jiang X; Ma L; Wu C; Yu Y; Chen Q
Biochem Biophys Res Commun; 2017 Nov; 493(1):718-722. PubMed ID: 28864414
[TBL] [Abstract][Full Text] [Related]
28. A quantitative evaluation of the effects of inhibitors of tubulin assembly on polymerization induced by discodermolide, epothilone B, and paclitaxel.
Dabydeen DA; Florence GJ; Paterson I; Hamel E
Cancer Chemother Pharmacol; 2004 May; 53(5):397-403. PubMed ID: 15060743
[TBL] [Abstract][Full Text] [Related]
29. Isocombretastatins A: 1,1-diarylethenes as potent inhibitors of tubulin polymerization and cytotoxic compounds.
Alvarez R; Alvarez C; Mollinedo F; Sierra BG; Medarde M; Peláez R
Bioorg Med Chem; 2009 Sep; 17(17):6422-31. PubMed ID: 19647439
[TBL] [Abstract][Full Text] [Related]
30. Linkages in tubulin-colchicine functions: the role of the ring C (C') oxygens and ring B in the controls.
Pérez-Ramírez B; Gorbunoff MJ; Timasheff SN
Biochemistry; 1998 Feb; 37(6):1646-61. PubMed ID: 9484236
[TBL] [Abstract][Full Text] [Related]
31. Computational comparison of microtubule-stabilising agents laulimalide and peloruside with taxol and colchicine.
Pineda O; Farràs J; Maccari L; Manetti F; Botta M; Vilarrasa J
Bioorg Med Chem Lett; 2004 Oct; 14(19):4825-9. PubMed ID: 15341932
[TBL] [Abstract][Full Text] [Related]
32. Competitive mass spectrometry binding assay for characterization of three binding sites of tubulin.
Li CM; Lu Y; Ahn S; Narayanan R; Miller DD; Dalton JT
J Mass Spectrom; 2010 Oct; 45(10):1160-6. PubMed ID: 20814887
[TBL] [Abstract][Full Text] [Related]
33. Conformationally restricted macrocyclic analogues of combretastatins.
Mateo C; Alvarez R; Pérez-Melero C; Peláez R; Medarde M
Bioorg Med Chem Lett; 2007 Nov; 17(22):6316-20. PubMed ID: 17889536
[TBL] [Abstract][Full Text] [Related]
34. Combretastatin-based compounds with therapeutic characteristics: a patent review.
Nainwal LM; Alam MM; Shaquiquzzaman M; Marella A; Kamal A
Expert Opin Ther Pat; 2019 Sep; 29(9):703-731. PubMed ID: 31369715
[No Abstract] [Full Text] [Related]
35. -NH-dansyl isocolchicine exhibits a significantly improved tubulin-binding affinity and microtubule inhibition in comparison to isocolchicine by binding tubulin through its A and B rings.
Das L; Datta AB; Gupta S; Poddar A; Sengupta S; Janik ME; Bhattacharyya B
Biochemistry; 2005 Mar; 44(9):3249-58. PubMed ID: 15736935
[TBL] [Abstract][Full Text] [Related]
36. Drugs that inhibit tubulin polymerization: the particular case of podophyllotoxin and analogues.
Desbène S; Giorgi-Renault S
Curr Med Chem Anticancer Agents; 2002 Jan; 2(1):71-90. PubMed ID: 12678752
[TBL] [Abstract][Full Text] [Related]
37. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery.
Wang Y; Zhang H; Gigant B; Yu Y; Wu Y; Chen X; Lai Q; Yang Z; Chen Q; Yang J
FEBS J; 2016 Jan; 283(1):102-11. PubMed ID: 26462166
[TBL] [Abstract][Full Text] [Related]
38. Morpholino derivatives of benzyl-benzodioxole, a study of structural requirements for drug interactions at the colchicine/podophyllotoxin binding site of tubulin.
Batra JK; Jurd L; Hamel E
Biochem Pharmacol; 1986 Nov; 35(22):4013-8. PubMed ID: 3778522
[TBL] [Abstract][Full Text] [Related]
39. Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains.
Naaz F; Haider MR; Shafi S; Yar MS
Eur J Med Chem; 2019 Jun; 171():310-331. PubMed ID: 30953881
[TBL] [Abstract][Full Text] [Related]
40. Structural and Biochemical Characterization of the Interaction of Tubulin with Potent Natural Analogues of Podophyllotoxin.
Antúnez-Mojica M; Rodríguez-Salarichs J; Redondo-Horcajo M; León A; Barasoain I; Canales Á; Cañada FJ; Jiménez-Barbero J; Alvarez L; Díaz JF
J Nat Prod; 2016 Aug; 79(8):2113-21. PubMed ID: 27518758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
